那他珠单抗治疗的多发性硬化患者发生进行性多灶性白质脑病时血清神经丝轻链升高
本研究分析两个欧洲队列共312例多发性硬化(MS)患者的血清神经丝轻链(NfL),其中25例进行性多灶性白质脑病(PML)、136例那他珠单抗治疗MS、151例未治疗MS。结果发现后续发生PML的患者NfL与其他那他珠单抗治疗MS患者相似,但PML起病时NfL较PML前状态及那他珠单抗治疗或未治疗MS患者高10倍,并持续升高至免疫重建炎症综合征(IRIS)起病。提示NfL可能是那他珠单抗治疗患者PML的早期可及标志物。
要点
- PML起病时血清NfL较PML前状态升高10倍。
- PML起病时NfL高于那他珠单抗治疗或未治疗MS患者。
- NfL持续升高直至IRIS起病,或可作PML早期标志物。
核心结论
- 在那他珠单抗治疗患者中,NfL可能代表PML的早期且可及的标志物。
研究设计与样本
- 分析两个欧洲队列共312例MS患者,包括25例PML、136例那他珠单抗治疗MS和151例未治疗MS患者。
主要发现
- 后续发生PML的患者NfL与其他那他珠单抗治疗MS患者相似。
- PML起病时NfL较PML前状态及那他珠单抗治疗或未治疗MS患者高10倍。
- NfL持续升高直至IRIS起病。
临床怎么用
- 对那他珠单抗治疗的MS患者,监测血清NfL可能有助于早期提示PML。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 multiple sclerosis (MS) patients to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment. The cohort comprised 25 PML, 136 natalizumab-treated, and 151 untreated MS patients. Patients subsequently developing PML had similar NfL to other natalizumab-treated MS patients. At PML onset, NfL were 10-fold higher than in the pre-PML condition and in natalizumab-treated or untreated MS patients, and NfL continued to increase until onset of immune reconstitution inflammatory syndrome. The results suggest that in natalizumab-treated patients, NfL may represent an early and accessible marker of PML. Ann Neurol 2019;85:606-610.
引用
- Dalla Costa G, Martinelli V, Moiola L, et al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol. 2019. PMID: 30761586. doi:10.1002/ana.25437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。